Marimastat
As of the edition of 20 October 2026, Marimastat is a small molecule: in active development; acts on MMP1, MMP2 and MMP3 and 2 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2027
- Kind
- Small molecule
- Registered trials
- 4, 0 stopped early
- Disease areas
- Cancer; Blood and lymph; Chemically induced; Heart and blood vessels; Inherited and neonatal; Injuries
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 1 | 0 | 1 | 0 |
| Phase 3 | 2 | 2 | 0 | 0 |
| All trials | 4 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| ILEX Oncology | Lead sponsor of trials | 1996 to now |